INBS Key Statistics, Chart & Performance
The current stock price of INBS is 10.94 USD. In the past month the price increased by 47.28%. In the past year, price decreased by -17.29%.
INBS Latest News, Press Relases and Analysis
INBS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.7 | 223.00B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.78 | 209.94B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.12 | 144.85B | ||
| SYK | STRYKER CORP | 27.74 | 139.73B | ||
| BDX | BECTON DICKINSON AND CO | 14.24 | 58.62B | ||
| IDXX | IDEXX LABORATORIES INC | 56.05 | 56.44B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.49 | 49.95B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.96 | 39.65B | ||
| RMD | RESMED INC | 25.2 | 36.41B | ||
| DXCM | DEXCOM INC | 37.53 | 27.23B | ||
| PODD | INSULET CORP | 64.37 | 20.69B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.74 | 18.82B |
Related stock screener links
About INBS
Company Profile
Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. The company is headquartered in New York City, New York and currently employs 16 full-time employees. The company went IPO on 2020-12-23. Its segment includes Commercially available Intelligent Fingerprinting Products and Development Stage Biosensor Platform Technology. Its product portfolio includes Intelligent Fingerprinting Platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader, and a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Biosensor Platform is designed to detect multiple biological analytes by substituting the top enzyme layer of the biosensor to suit each analyte and to develop a range of Point of Care Tests, including the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology.
Company Info
INTELLIGENT BIO SOLUTIONS IN
135 W 41St St,, Floor 5
New York City NEW YORK US
Employees: 50
Phone: 16467905756
INTELLIGENT BIO SOLUTIONS IN / INBS FAQ
Can you describe the business of INTELLIGENT BIO SOLUTIONS IN?
Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. The company is headquartered in New York City, New York and currently employs 16 full-time employees. The company went IPO on 2020-12-23. Its segment includes Commercially available Intelligent Fingerprinting Products and Development Stage Biosensor Platform Technology. Its product portfolio includes Intelligent Fingerprinting Platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader, and a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Biosensor Platform is designed to detect multiple biological analytes by substituting the top enzyme layer of the biosensor to suit each analyte and to develop a range of Point of Care Tests, including the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology.
What is the stock price of INTELLIGENT BIO SOLUTIONS IN today?
The current stock price of INBS is 10.94 USD. The price decreased by -0.55% in the last trading session.
Does INTELLIGENT BIO SOLUTIONS IN pay dividends?
INBS does not pay a dividend.
What is the ChartMill rating of INTELLIGENT BIO SOLUTIONS IN stock?
INBS has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is INTELLIGENT BIO SOLUTIONS IN (INBS) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on INBS.
INBS Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to INBS. When comparing the yearly performance of all stocks, INBS is a bad performer in the overall market: 76.89% of all stocks are doing better.
INBS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to INBS. INBS has a bad profitability rating. Also its financial health evaluation is rather negative.
INBS Financial Highlights
Over the last trailing twelve months INBS reported a non-GAAP Earnings per Share(EPS) of -12.81. The EPS increased by 54.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -108.25% | ||
| ROE | -300.07% | ||
| Debt/Equity | 0.04 |
INBS Forecast & Estimates
For the next year, analysts expect an EPS growth of 128% and a revenue growth 126.26% for INBS